KBLB: AI 评分 44/100 — AI 分析 (4月 2026)

Kraig Biocraft Laboratories, Inc. develops protein-based fibers using recombinant DNA technology. The company targets technical textile and specialty fiber industries with applications in defense, industrial, and medical sectors.

Key Facts: AI Score: 44/100 Sector: Basic Materials

公司概况

概要：

Kraig Biocraft Laboratories, Inc. specializes in developing and commercializing protein-based fibers, leveraging recombinant DNA technology for applications in technical textiles and specialty fibers. Targeting diverse sectors including defense, industrial, and medical, the company aims to disrupt traditional material science with innovative, high-performance solutions.

KBLB是做什么的？

Kraig Biocraft Laboratories, Inc., founded in 2006 and headquartered in Ann Arbor, Michigan, is a biotechnology company focused on the development and commercialization of protein-based fibers. The company utilizes recombinant DNA technology to create advanced materials with unique properties, targeting the technical textile and specialty fiber industries. Kraig Biocraft's core innovation lies in genetically engineering silkworms to produce spider silk, a material known for its exceptional strength, elasticity, and toughness. These spider silk-based fibers are designed for a wide range of applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company's products also cater to niche markets such as medical textiles, geotextiles, defense and military textiles, protective clothing, filtration textiles, and functional textiles for buildings and transportation. Kraig Biocraft aims to replace traditional materials with sustainable, high-performance alternatives, positioning itself as a key player in the advanced materials sector.

KBLB的投资论点是什么？

Kraig Biocraft Laboratories presents a high-risk, high-reward investment opportunity centered on its proprietary spider silk technology. The company's potential lies in disrupting the technical textile and specialty fiber markets with a sustainable, high-performance alternative to traditional materials. Key value drivers include successful scaling of spider silk production, securing significant contracts in target markets such as defense and aerospace, and achieving profitability. However, the company's negative profit margin of -13698.5% and negative gross margin of -15.1% highlight significant financial challenges. Upcoming catalysts include potential advancements in production efficiency and new partnerships. Investors should closely monitor the company's ability to secure funding and achieve commercial viability.

KBLB在哪个行业运营？

Kraig Biocraft Laboratories operates within the specialty chemicals industry, a sector characterized by innovation in material science and increasing demand for high-performance and sustainable materials. The technical textile market, a key target for Kraig Biocraft, is projected to grow, driven by advancements in material technology and increasing applications in defense, aerospace, and healthcare. Competition includes established chemical companies and emerging biotech firms focused on advanced materials. Kraig Biocraft aims to differentiate itself through its proprietary spider silk technology, offering a unique combination of strength, elasticity, and sustainability.

Chemicals - Specialty

Basic Materials

KBLB有哪些增长机遇？

Growth opportunity 1: Expansion into the defense and military textiles market represents a significant growth opportunity for Kraig Biocraft. Spider silk's exceptional strength and ballistic protection capabilities make it an ideal material for body armor and other protective gear. Securing contracts with defense agencies could drive substantial revenue growth. The global military textiles market is projected to reach billions of dollars, offering a large addressable market for Kraig Biocraft. Timeline: Ongoing.
Growth opportunity 2: Penetration of the aerospace composite materials market offers another avenue for growth. Spider silk can be used to reinforce composite materials, enhancing their strength and durability while reducing weight. This is particularly valuable in the aerospace industry, where weight reduction translates to fuel efficiency and improved performance. The aerospace composite materials market is expected to grow, driven by increasing demand for lightweight and fuel-efficient aircraft. Timeline: Ongoing.
Growth opportunity 3: Development of medical textile applications for spider silk presents a high-value growth opportunity. Spider silk's biocompatibility and strength make it suitable for sutures, wound dressings, and tissue scaffolds. The medical textiles market is growing, driven by advancements in healthcare technology and increasing demand for biocompatible materials. Kraig Biocraft can partner with medical device companies to develop and commercialize spider silk-based medical products. Timeline: Ongoing.
Growth opportunity 4: Licensing of Kraig Biocraft's spider silk technology to other companies in the textile and materials industries could generate significant revenue streams. Licensing agreements would allow other companies to utilize Kraig Biocraft's technology to develop and commercialize their own spider silk-based products. This strategy would expand the reach of Kraig Biocraft's technology and generate recurring revenue. Timeline: Ongoing.
Growth opportunity 5: Improving production efficiency and scaling up spider silk production is crucial for achieving profitability and meeting market demand. Investing in research and development to optimize silkworm breeding and silk extraction processes can significantly reduce production costs and increase output. This will enable Kraig Biocraft to compete more effectively with traditional materials and capture a larger share of the market. Timeline: Ongoing.

Market capitalization of $0.13 billion indicates a small-cap company with potential for growth but also higher volatility.
P/E ratio of -35.29 reflects the company's current lack of profitability, suggesting it is an early-stage growth company.
Profit Margin of -13698.5% highlights significant operational inefficiencies and challenges in achieving profitability.
Gross Margin of -15.1% indicates that the company's cost of goods sold exceeds its revenue, requiring substantial improvements in production efficiency.
Beta of 1.33 suggests the stock is more volatile than the market, indicating higher risk and potential for larger price swings.

KBLB提供哪些产品和服务？

Develops protein-based fibers using recombinant DNA technology.
Engineers silkworms to produce spider silk.
Creates advanced materials with unique properties.
Targets the technical textile and specialty fiber industries.
Offers spider silk-based fibers for ballistic protection.
Provides materials for industrial cables and safety equipment.
Develops composite materials for the aerospace industry.

KBLB如何赚钱？

Develops and patents recombinant DNA technology for spider silk production.
Produces spider silk fibers through genetically engineered silkworms.
Sells spider silk fibers to manufacturers in various industries.
Potentially licenses its technology to other companies for revenue.

Manufacturers of ballistic protection equipment.
Companies producing industrial cables and safety equipment.
Aerospace companies using composite materials.
Medical device companies requiring biocompatible materials.

Proprietary recombinant DNA technology for spider silk production.
Patents protecting its spider silk technology.
First-mover advantage in the spider silk market.
Potential for strong brand recognition as a leader in advanced materials.

什么因素可能推动KBLB股价上涨？

Upcoming: Potential advancements in spider silk production efficiency.
Upcoming: Securing new contracts in the defense or aerospace sectors.
Ongoing: Research and development efforts to expand applications of spider silk.
Ongoing: Partnerships with industry leaders to commercialize spider silk products.
Ongoing: Efforts to improve financial performance and achieve profitability.

KBLB的主要风险是什么？

Ongoing: Negative profit margin and gross margin indicate financial instability.
Potential: Competition from established material companies.
Potential: Technological advancements by competitors.
Potential: Regulatory hurdles and compliance requirements.
Ongoing: Reliance on successful scaling of spider silk production.

KBLB的核心优势是什么？

Proprietary spider silk technology.
Potential for high-performance materials.
Sustainable and eco-friendly production process.
Diverse range of potential applications.

KBLB的劣势是什么？

Negative profit margin and gross margin.
Limited commercial production capacity.
Reliance on successful scaling of production.
Competition from established material companies.

KBLB有哪些机遇？

Expansion into defense, aerospace, and medical markets.
Licensing of spider silk technology.
Partnerships with industry leaders.
Increasing demand for sustainable materials.

KBLB面临哪些威胁？

Competition from alternative materials.
Technological advancements by competitors.
Regulatory hurdles and compliance requirements.
Economic downturn affecting demand for specialty materials.

KBLB的竞争对手是谁？

Asahi Kasei Corp — Diversified chemical company with a broad range of materials. — (ABSSF)
Bayer AG — Global pharmaceutical and chemical company. — (BCEKF)
Bio-Synthesis Technologies, Inc. — Focuses on specialty chemicals and materials. — (BLSTF)
Glanbia PLC — Nutrition company that produces specialty proteins. — (GLNLF)
Grupa Azoty SA — Chemical company producing a variety of products. — (GMGMF)

Key Metrics

MoonshotScore: 44/100

Company Profile

CEO: Kim Kraig Thompson
Headquarters: Ann Arbor, US
Employees: 37
Founded: 2008

AI Insight

AI analysis pending for KBLB

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Kraig Biocraft Laboratories, Inc. do?

Kraig Biocraft Laboratories, Inc. is a biotechnology company that specializes in developing protein-based fibers using recombinant DNA technology. The company's primary focus is on producing spider silk through genetically engineered silkworms. This spider silk is then used to create advanced materials for various applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company aims to replace traditional materials with sustainable, high-performance alternatives.

What do analysts say about KBLB stock?

As of 2026-03-17, there is no available analyst consensus on Kraig Biocraft Laboratories, Inc. (KBLB). The company's financial metrics, including a negative profit margin of -13698.5% and a negative gross margin of -15.1%, suggest significant financial challenges. Investors should carefully consider the company's high-risk, high-reward profile, potential for disruption in the technical textile market, and ability to achieve commercial viability before making any investment decisions.

What are the main risks for KBLB?

The main risks for Kraig Biocraft Laboratories, Inc. include its current financial instability, as evidenced by its negative profit and gross margins. The company faces competition from established material companies and the potential for technological advancements by competitors. Regulatory hurdles and compliance requirements could also pose challenges. Additionally, the company's success depends on its ability to successfully scale up spider silk production and secure significant contracts in its target markets.